流动性方面，港股创新药50ETF盘中换手9.25%，成交2.73亿元。资金流入方面，拉长时间看，港股创 新药50ETF近19个交易日内，合计"吸金"2.31亿元。 2026年A股首个交易日，三大指数集体上涨，医疗服务、CRO等板块概念涨幅居前。截至 10:36，中证 港股通创新药指数(931250)强势上涨3.86%，成分股昭衍新药上涨11.32%，泰格医药上涨7.07%，科伦博 泰生物-B上涨6.69%，云顶新耀、信达生物等个股跟涨。港股创新药50ETF(513780)上涨5.30%。拉长时 间看，截至2025年12月31日，港股创新药50ETF近1年累计上涨67.18%。 港股创新药50ETF（513780）跟踪中证港股通创新药指数，可T+0交易，指数囊括药明生物、信达生 物、百济神州等港股创新药龙头，该指数生物制品+化学制药权重占比近90%，助力高效布局高弹性港 股创新药板块。该基金还设置了场外联接基金（A类：023597，C类：023598），场外投资者可保持关 注。 从估值层面来看，港股创新药50ETF跟踪的中证港股通创新药指数最新市盈率（PE-TTM）仅31.23倍， 处于近3年16.75%的分位 ...

12月22日，创业板指、科创50双双涨超2%，多只跟踪半导体材料设备、通信设备、5G通信等指数的ETF涨超4%。 02 临近年末，A500ETF、科创债ETF成为股债"双子星"。今日A500ETF总成交额突破600亿元大关，创下历史天量，4只龙头 单品成交额均突破百亿元；另有两只科创债ETF今日成交额达140亿元以上。 01 03 上周（12月15日至12月19日），资金抢筹力度显著加大，跟踪中证A500指数的ETF合计净流入超320亿元，A500ETF南方 （159352）净流入超百亿元，A500ETF华泰柏瑞（563360）净流入超80亿元。 半导体相关ETF领涨 12月22日，多只跟踪半导体材料设备、通信设备、中证半导、5G通信等指数的ETF涨超4%。其中，通信ETF（515880） 今年以来涨幅已达125.95%，排名市场前列，截至12月19日的最新规模突破133亿元，是目前全市场规模最大的通信主题 ETF产品。 标普生物科技ETF（159502）、纳指生物科技ETF（513290）今日涨幅也在4%以上。但值得注意的是，两只QDII产品溢 价率同步飙升，纳指生物科技ETF（513290）溢价率已突破7 ...

ETF方面，美股生物科技板块走高，嘉实基金标普生物科技ETF、汇添富基金纳指生物科技ETF分别涨 5.01%和4.88%。 半导体板块全线上扬，国泰基金半导体设备ETF、广发基金芯片设备ETF、万家基金半 导体设备ETF基金分别涨4.93%、4.92%和4.82%。CPO板块强势反弹，国泰基金通信ETF和博时基金 5G50ETF涨4%。 黄金再创历史新高，华夏基金黄金股ETF、平安基金黄金股票ETF基金涨3.7%。 港股医疗板块走低， 港股创新药50ETF、恒生生物科技ETF、港股医疗ETF、港股通医疗ETF跌1%。影 视股走弱，影视ETF跌1.29%。 财经频道更多独家策划、专家专栏，免费查阅>> A股重返3900点，截至收盘， 上证指数涨0.69%， 深证成指涨1.47%， 创业板指涨2.23%， 北证50涨 0.24%。全市场成交额18650亿元，较上日成交额放量1163亿元。 板块题材上，海南、 存储芯片、贵金 属板块活跃， 医药商业、 影视院线板块调整。 责任编辑：钟离 ...

来源：上海证券报·中国证券网 上证报中国证券网讯 12月19日，ETF午间收盘涨跌不一，港股医疗ETF(159366)涨3.56%，港股通医疗 ETF(520510)涨3.14%，港股创新药50ETF(513780)涨3.00%，标普油气ETF(513350)跌1.07%，深证 100ETF华安(159706)跌0.67%，标普油气ETF(159518)跌0.66%。 来源：上海证券报·中国证券网 上证报中国证券网讯 12月19日，ETF午间收盘涨跌不一，港股医疗ETF(159366)涨3.56%，港股通医疗 ETF(520510)涨3.14%，港股创新药50ETF(513780)涨3.00%，标普油气ETF(513350)跌1.07%，深证 100ETF华安(159706)跌0.67%，标普油气ETF(159518)跌0.66%。 ...

Core Viewpoint - The Hong Kong Innovative Drug 50 ETF (513780) experienced a slight decline of 0.29% on December 1, with a trading volume of 285 million yuan, indicating a decrease in investor interest and market activity [1] Fund Performance - The fund's latest net asset value is calculated at 2.992 billion yuan, with a total share count of 1.732 billion, reflecting a reduction of 14 million shares on the day and a total decrease of 81.5 million shares over the past 20 trading days [1] - Since its inception on October 16, 2024, the fund has achieved a return of 72.76%, while the return over the past month has been -0.86% [1] Management Information - The fund is managed by Invesco Great Wall Fund Management Co., Ltd., with Jin Huang serving as the fund manager [1]

Market Overview - The A-share market opened lower but rebounded, with the Shanghai Composite Index up 0.21%, the Shenzhen Component Index up 0.72%, and the ChiNext Index up 0.71 [1] - Total market turnover reached 983.6 billion yuan, a decrease of 113.4 billion yuan compared to the previous day [1] - Over 3,500 stocks in the market experienced gains [1] Sector Performance - The lithium mining sector continued to rebound, while the consumer sectors in Fujian and Hainan remained active [1] - Semiconductor equipment and oil & gas stocks performed well, with the CPO concept recovering in the morning session [1] - The pharmaceutical and banking sectors experienced corrections, and AI application sectors remained sluggish [1] ETF Performance - The semiconductor equipment sector led the gains in ETFs, with several funds such as Huaxia Fund's Sci-Tech Semiconductor ETF and Haitai Baipin Fund's Sci-Tech Semiconductor Equipment ETF rising over 3% [1] - The rare metals sector also saw a rebound, with ICBC Credit Suisse's Rare Metals ETF and GF Fund's Rare Metals ETF increasing by 2% and 1.99%, respectively [1] - Oil & gas stocks showed strong performance, with the Yinhua Fund's Oil & Gas Resources ETF rising by 1.84% [1] - The traditional Chinese medicine sector lagged, with both the Chinese Medicine 50 ETF and the Chinese Medicine ETF declining by 1% [1] - The Hong Kong innovative drug sector fell, with the Hang Seng Medical ETF and the Hong Kong Innovative Drug 50 ETF both down by 1% [1]

Core Viewpoint - The Hong Kong Innovative Drug 50 ETF (513780) has shown significant growth, with a 44.49% increase over the past six months, indicating strong performance in the innovative pharmaceutical sector [1][2] Group 1: ETF Performance - As of October 27, 2025, the Hong Kong Innovative Drug 50 ETF rose by 1.16%, reaching a peak increase of over 2% during the trading session [1] - The ETF ranks first among similar index funds in terms of growth, reflecting robust investor interest in innovative pharmaceuticals [1] Group 2: Company Earnings - WuXi AppTec reported a revenue of 32.857 billion yuan for the first three quarters of 2025, marking an 18.61% year-on-year increase, with a net profit of 12.076 billion yuan, up 84.84% [1] - In Q3 2025, the company achieved a revenue of 12.057 billion yuan, a 15.26% increase year-on-year, and a net profit of 3.515 billion yuan, reflecting a 53.27% growth [1] Group 3: Market Trends and Insights - Everbright Securities noted that the Federal Reserve has initiated a rate-cutting cycle, which is favorable for the innovative pharmaceutical sector, particularly for innovative drugs and devices [1] - The current investment focus in the pharmaceutical industry should emphasize clinical value, addressing patient needs, with both domestic and international policies providing higher premiums for clinical value [1] - The reduction in interest rates is expected to improve the financing environment for pharmaceutical companies, particularly benefiting biotech firms and increasing demand for CXO services, positively impacting new orders and performance growth [1] Group 4: Industry Dynamics - The innovative drug market is transitioning from a broad rally to a focus on "quality factors," where only leading innovative drugs with strong clinical data and commercialization capabilities will achieve financial success [2] - The Hong Kong Innovative Drug 50 ETF tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes leading companies like WuXi Biologics, Innovent Biologics, and BeiGene, with nearly 90% weight in biopharmaceuticals and chemical drugs [2] - The ETF allows T+0 trading and has established off-market connection funds for investors to maintain interest in the high-volatility Hong Kong innovative drug sector [2]

Group 1 - The core viewpoint highlights a strong performance in the Hong Kong innovative drug sector, with the CSI Hong Kong Stock Connect Innovative Drug Index rising by 2.29% and significant gains in constituent stocks such as 3SBio, CanSino Biologics, and Rongchang Biologics [1] - The Hong Kong Innovative Drug 50 ETF has seen a half-day increase of 1.61%, with a notable trading volume of 4.73 billion yuan and a turnover rate of 14.12%, indicating active market participation [1] - In the first nine months of the year, the total value of Chinese innovative drug patent overseas contracts exceeded 100 billion USD, marking a 170% year-on-year increase, suggesting a robust growth trend in the sector [1] Group 2 - Recent reports indicate a slight pullback in the pharmaceutical sector, presenting potential investment opportunities, driven by a recovery in capital market financing and an increase in innovative drug overseas transaction volumes [2] - The CXO industry is expected to see performance recovery in the second half of 2025, supported by the anticipated effects of U.S. interest rate cuts [2] - The Hong Kong Innovative Drug 50 ETF tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes leading companies in the sector, and is positioned for efficient investment in the high-volatility Hong Kong innovative drug market [2]

Group 1 - The core viewpoint of the articles highlights a significant upward trend in the Hong Kong pharmaceutical sector, with various ETFs experiencing gains of over 3% amid a broader market recovery in A-shares [1] - The upcoming European Society for Medical Oncology (ESMO) conference in October 2025 is expected to be a key event, with new research abstracts to be presented, which may influence market sentiment [1] - In the first half of 2025, China has seen a total of 72 License-out transactions, surpassing half of the total transactions for 2024, with a 16% increase in total transaction value compared to the previous year [2] Group 2 - The trend of Chinese innovative drugs going global is driven by continuous innovation and efficiency improvements, despite concerns over potential trade conflicts [2] - The pharmaceutical sector is expected to experience a reversal in 2025, with a focus on innovative drugs and addressing unmet clinical needs, particularly in the dual/multi-antibody and ADC sectors [3] - The upcoming ESMO conference is anticipated to showcase clinical data from Chinese innovative drugs, which could be a major market catalyst, alongside the release of Q3 earnings reports and national healthcare negotiations in November [3]

Core Viewpoint - The Hong Kong stock market has shown significant rebound since September, attracting more investors, leading to the launch of the Invesco Great Wall Hang Seng Stock Connect 50 ETF on September 18, which aims to help investors efficiently capture market opportunities [1]. Group 1: ETF Product Overview - The Invesco Great Wall Hang Seng Stock Connect 50 ETF tracks the Hang Seng Stock Connect 50 Index, which selects 50 highly liquid leading companies listed in Hong Kong, covering both new economy and traditional sectors [1]. - The index represents 52% of the market's circulating market value and 56% of net profits, making it a key representation of core assets in the Hong Kong stock market [1]. - The top four industries in the index are consumer, finance, technology, and pharmaceuticals, which together account for 85.82% of the index's weight, effectively covering popular assets in the Hong Kong market [1]. Group 2: Company Strategy and Product Line - Invesco Great Wall Fund has been expanding its ETF product line, creating a diverse "Hong Kong Stock Family" that includes various ETFs focusing on technology, new consumption, biotechnology, and multi-strategy dividend ETFs [2]. - The launch of the Invesco Great Wall Hang Seng Stock Connect 50 ETF further enhances the company's offerings in Hong Kong index products, completing an important piece of its product puzzle [2].